Xintiandi: Announcement on changes in the company\'s pharmaceutical production license
Xintiandi: Notice on completing registration of industrial and commercial changes and issuing business licenses
Xintiandi: Legal Opinions of Beijing Tianyuan Law Firm on the 2024 Second Extraordinary Shareholders\' Meeting of Xintiandi Pharmaceutical Co., Ltd.
Xintiandi: Announcement of Resolutions of the 2024 Second Extraordinary General Meeting of Shareholders
Xintiandi: Notice on Convening the Second Extraordinary General Meeting of Shareholders in 2024
Xintiandi: Board of Directors Rules of Procedure
Xintiandi: Announcement on the adjustment of product types for some fund-raising projects and the internal investment restructuring and extension of some fund-raising projects
Xintiandi: General Manager Work Rules
Xintiandi: Announcement on the revision of the “Articles of Association” and the revision and addition of relevant governance systems
Xintiandi: An indicative announcement on the disclosure of the report for the third quarter of 2024
Xintiandi: Board Secretary Work Rules
Xintiandi: Announcement on Obtaining a Notice of Approval of the Application for the Marketing of Chemical Ingredients
Xintiandi: Announcement on Obtaining a Notice of Approval of the Application for the Marketing of Chemical Ingredients
Xintiandi: Announcement of Resolutions of the 2024 First Extraordinary General Meeting of Shareholders
Xintiandi: Legal Opinions of Beijing Tianyuan Law Firm on the 2024 First Extraordinary General Meeting of Shareholders of Xintiandi Pharmaceutical Co., Ltd.
Newland Pharmaceutical: Correction announcement regarding the notice of convening the first extraordinary shareholders' meeting in 2024.
Newland Pharmaceutical: Announcement on the Disclosure of 2024 Half-Year Report
Newland Pharmaceutical: Summary table of non-operational fund occupancy and other related fund transactions in the first half of 2024.
Newland Pharmaceutical: Notice of the first temporary shareholder meeting in 2024
Newland Pharmaceutical: New World Pharma Co., Ltd. 2024 interim financial report.
No Data